American Heart Journal Plus · Jan 14, 2026

SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy

By Sheashaa H, Ibrahim R, Pham HN et al.

BACKGROUND: HIV cardiomyopathy (HIV-CM) is associated with significant morbidity and mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have benefits in heart failure (HF), but their role in the specialized population of HIV-CM is poorly understood. METHODS: Patients in the TriNetX Network with HIV-CM and SGLT2i therapy were compared to a propensity matched control group of patients with HIV-CM without SGLT2i use. The primary endpoint was all-cause mortality, secondary endpoints included all-cause hospitalizations, acute HF, stroke, acute myocardial infarction (MI), cardiac arrest, atrial fibrillation and ventricular tachycardia. RESULTS: In the total of 2606 included patients, SGLT2i therapy was associated with significant reduction in all-cause mortality (HR 0.475, 95%CI 0.337-0.671), all-cause hospitalization (HR 0.725, 95%CI 0.646-0.814). No significant differences were observed in the individual outcomes of acute HF, MI, stroke, or cardiac arrest. CONCLUSION: SGLT2i use was associated with significant reductions in all-cause mortality and hospitalizations in patients with HIV-CM.

doi.org/10.1016/j.ahjo.2026.100722Open accessPubMed 41608154Interventions